Market Overview - On September 12, the medical device sector declined by 0.72%, with Shanwaishan leading the drop [1] - The Shanghai Composite Index closed at 3883.69, up 0.22%, while the Shenzhen Component Index closed at 12996.38, up 0.13% [1] Top Gainers in Medical Device Sector - Haobobo (688656) closed at 173.11, up 18.16% with a trading volume of 21,900 lots and a transaction value of 333 million [1] - Tianchen Medical (688013) closed at 67.57, up 11.10% with a trading volume of 30,800 lots and a transaction value of 197 million [1] - Toukeng Life (300642) closed at 27.41, up 10.39% with a trading volume of 185,700 lots and a transaction value of 482 million [1] - Zhend Medical (603301) closed at 35.64, up 10.00% with a trading volume of 64,400 lots and a transaction value of 228 million [1] Top Losers in Medical Device Sector - Shanwaishan (688410) closed at 15.35, down 4.78% with a trading volume of 142,500 lots and a transaction value of 216 million [2] - Aojing Medical (688613) closed at 26.03, down 3.38% with a trading volume of 77,200 lots and a transaction value of 202 million [2] - Jiming Health (603222) closed at 13.66, down 2.84% with a trading volume of 1,008,500 lots and a transaction value of 1.382 billion [2] Capital Flow Analysis - The medical device sector experienced a net outflow of 199 million from institutional investors, while retail investors saw a net inflow of 256 million [2] - Retail investors had a net outflow of 57.41 million [2] Individual Stock Capital Flow - Sainuo Medical (688108) had a net inflow of 127 million from institutional investors, while retail investors experienced a net outflow of 11.9 million [3] - Toukeng Life (300642) saw a net inflow of 56.51 million from institutional investors, with a net outflow of 5.40 million from retail investors [3] - Meihua Medical (301363) had a net inflow of 31.17 million from institutional investors, while retail investors had a net outflow of 1.08 million [3]

Company Overview - Shanghai TuoJing Life Technology Co., Ltd. is located at 412 Huiqing Road, Pudong New District, Shanghai, established on November 6, 2003, and listed on April 21, 2017. The company specializes in the research, production, and sales of in vitro diagnostic products under its own brand [1]. Business Performance - The main revenue composition of the company includes: 92.50% from reagent sales, 6.20% from instrument sales, 1.26% from services, and 0.04% from materials [1]. - As of September 12, the stock price increased by 5.03%, reaching 26.08 CNY per share, with a trading volume of 221 million CNY and a turnover rate of 6.43%, resulting in a total market capitalization of 4.239 billion CNY [1]. Shareholder Information - CITIC Prudential Fund has a fund that entered the top ten circulating shareholders of TuoJing Life, specifically the CITIC Prudential Multi-Strategy Mixed (LOF) A (165531), which acquired 1.2039 million shares, accounting for 0.87% of circulating shares. The estimated floating profit today is approximately 1.5049 million CNY [2]. - The fund was established on June 16, 2017, with a latest scale of 1.245 billion CNY. Year-to-date returns are 40.07%, ranking 1467 out of 8174 in its category; the one-year return is 77.36%, ranking 1081 out of 7981; and since inception, the return is 137.18% [2]. Fund Management - The fund managers of CITIC Prudential Multi-Strategy Mixed (LOF) A are Jiang Feng and Wang Ying. Jiang Feng has a cumulative tenure of 5 years and 153 days, with a total fund asset size of 5.782 billion CNY, achieving a best fund return of 125.39% and a worst return of 2.45% during his tenure [3]. - Wang Ying has a cumulative tenure of 8 years and 211 days, managing a total fund asset size of 3.835 billion CNY, with a best fund return of 49.08% and a worst return of -8.42% during her tenure [3].

Group 1 - The core point of the article is that Tsinghua Tongfang Life Science has announced the receipt of a patent certificate for an invention by the company and its wholly-owned subsidiary, Shanghai Tsinghua Tongfang Diagnostic Technology Co., Ltd [2] Group 2 - The announcement was made on the evening of September 10 [2] - The patent is expected to enhance the company's technological capabilities and competitive position in the life sciences industry [2] - This development may lead to potential growth opportunities for the company in the diagnostic technology sector [2]

证券代码：300642 证券简称：透景生命 公告编号：2025-064 上述发明专利系公司及全资子公司自主研发，提供一种可对粪便样本有效采 样，粪便样本液的快速卫生的制取，以及准确便利的粪便样本检测方法，暂未应 用于公司产品。上述专利证书的取得不会对公司业绩产生重大影响，但在一定程 度上有利于发挥公司及全资子公司的自主知识产权优势，完善知识产权保护体系， 形成持续创新机制，提升公司的核心竞争力。 特此公告。 上海透景生命科技股份有限公司 董 事 会 2025 年 09 月 10 日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 上海透景生命科技股份有限公司（以下简称"透景生命"或"公司"）及全 资子公司上海透景诊断科技有限公司（以下简称"透景诊断"或"全资子公司"） 于近日收到中华人民共和国国家知识产权局颁发的 1 项发明专利证书，具体情况 如下： | 专利名称 | | 专利号 | | 专利权人 | 专利类型 | 申请日期 | | 有效期 | | 证书号 | | | --- | --- | --- | --- | --- | --- | --- | --- ...

Market Overview - On September 9, the medical device sector declined by 0.99%, with TuoJing Life leading the drop [1] - The Shanghai Composite Index closed at 3807.29, down 0.51%, while the Shenzhen Component Index closed at 12510.6, down 1.23% [1] Stock Performance - Notable gainers in the medical device sector included: - ZhenDe Medical (603301) with a closing price of 29.71, up 10.00% [1] - JiMin Health (603222) at 12.55, up 8.56% [1] - KangWei Century (688426) at 27.60, up 5.18% [1] - Conversely, significant decliners included: - TuoJing Life (300642) at 24.18, down 7.82% [2] - SaiNuo Medical (688108) at 30.02, down 7.63% [2] - SanYou Medical (688085) at 20.49, down 7.54% [2] Capital Flow - The medical device sector experienced a net outflow of 8.83 billion yuan from institutional investors, while retail investors saw a net inflow of 6.97 billion yuan [2][3] - Notable capital flows included: - JiAn Medical (002432) with a net inflow of 64.14 million yuan from institutional investors [3] - ZhenDe Medical (603301) with a net inflow of 56.97 million yuan from institutional investors [3]

Company Overview - Shanghai TuoJing Life Technology Co., Ltd. is located at 412 Huiqing Road, Pudong New District, Shanghai, established on November 6, 2003, and listed on April 21, 2017. The company specializes in the research, production, and sales of in vitro diagnostic products under its own brand [1]. Financial Performance - As of June 30, 2025, TuoJing Life reported a revenue of 159 million yuan, a year-on-year decrease of 26.25%, and a net profit attributable to shareholders of 2.76 million yuan, down 58.41% year-on-year [2]. - Cumulative cash dividends since the A-share listing amount to 264 million yuan, with 81.36 million yuan distributed over the past three years [3]. Stock Performance - On September 9, TuoJing Life's stock price fell by 2.02% to 25.70 yuan per share, with a trading volume of 108 million yuan and a turnover rate of 3.00%, resulting in a total market capitalization of 4.178 billion yuan [1]. - The stock has increased by 83.94% year-to-date, with a recent decline of 4.28% over the last five trading days, a 47.62% increase over the last 20 days, and a 79.72% increase over the last 60 days [1]. Shareholder Information - As of June 30, 2025, the number of shareholders is 16,000, a decrease of 6.19% from the previous period, with an average of 8,614 circulating shares per person, an increase of 6.60% [2]. - Among the top ten circulating shareholders, CITIC Prudential Multi-Strategy Mixed Fund (LOF) A ranks as the seventh largest shareholder, holding 1.2039 million shares as a new shareholder [3]. Market Position - TuoJing Life operates within the pharmaceutical and biotechnology sector, specifically in medical devices and in vitro diagnostics. The company is associated with several concept sectors, including share buybacks, DeepSeek concept, specialized and innovative enterprises, multiple births concept, and the Shanghai Free Trade Zone [1].

Group 1 - The company announced a stock buyback program, having repurchased a total of 287,900 shares as of August 31, 2025 [2] - The repurchased shares represent 0.18% of the company's current total share capital [2]

Company Summary - Tuojing Life announced a share buyback of approximately 290,000 shares, accounting for 0.18% of the company's total share capital, with a total expenditure of approximately RMB 8.15 million [1] - The highest and lowest prices for the repurchased shares were RMB 29.34 and RMB 27.3 per share, respectively [1] - As of the report, Tuojing Life's market capitalization stands at RMB 4.4 billion [1] Industry Summary - For the fiscal year 2024, Tuojing Life's revenue is entirely derived from the in vitro diagnostics industry, with a 100% contribution from this sector [1]

Group 1 - The company, Tsinghua Tongfang Co., Ltd. (透景生命), announced a share buyback program, having repurchased a total of 287,900 shares as of August 31, 2025, which represents 0.18% of its current total share capital [1] - The highest price at which the shares were repurchased was 29.34 CNY per share, while the lowest price was 27.30 CNY per share [1] - The total amount spent on the share buyback was 8.1499 million CNY, excluding transaction fees [1]

证券代码：300642 证券简称：透景生命 公告编号：2025-063 上海透景生命科技股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 上海透景生命科技股份有限公司（以下简称"公司"）于 2025 年 4 月 8 日 召开第四届董事会第八次会议，审议通过了《关于以集中竞价交易方式回购公司 股份的议案》。本次回购的股份用于股权激励或员工持股计划，用于回购股份的 资金总额不低于人民币 2,000 万元（含）且不超过人民币 4,000 万元（含），回 购股份价格不超过 16.00 元/股（含），实施期限为自公司董事会审议通过本次 回购股份方案之日起 12 个月内。具体内容请详见公司分别于 2025 年 4 月 8 日、 2025 年 4 月 14 日在巨潮资讯网（www.cninfo.com.cn）披露的《关于公司以集 中竞价交易方式回购股份方案的公告》（公告编号：2025-008）、《回购报告书》 （公告编号：2025-010）。 因公司2024年度权益分派已实施完毕，自2024年度权益分派除权除息日（即 2025 年 5 ...